Form 4: Regeneron Executive George Yancopoulos Reports Stock Transfers
SEC Form 4 Filing
George Yancopoulos, a top executive at Regeneron Pharmaceuticals, reported the transfer of company stock via gift and trust arrangements.
Summary
- George Yancopoulos, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, reported transactions involving the company's common stock on June 10, 2024.
- He transferred 75,799 shares of common stock indirectly via a 2022 GRAT II.
- He acquired 37,900 shares of common stock indirectly held by children.
- Yancopoulos directly owns 868,994 shares of Regeneron common stock.
- He indirectly owns 5,903 shares via a 401(k) plan and 180,000 shares via a trust for children.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often related to compensation, estate planning, or diversification strategies.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of stock transactions (gift and acquisition). |
| 06/12/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.